Methodological quality of systematic reviews referenced in clinical practice guidelines for the treatment of opioid use disorder

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Ross, Andrew ^a   Rankin, Justin ^a   Beaman, Jason ^a   Murray, Kelly ^a   Sinnett, Philip ^a   Riddle, Ross ^a   Haskins, Jordan ^a   Vassar, Matt ^a  

^a OKLAHOMA STATE UNIVERSITY CENTER FOR HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; HEALTH CARE QUALITY; HUMAN; META ANALYSIS; METHODOLOGY; OPIATE ADDICTION; PATIENT CARE; PRACTICE GUIDELINE; REFERENCE DATABASE; SYSTEMATIC REVIEW; EVIDENCE BASED MEDICINE; LITERATURE; META ANALYSIS (TOPIC); OPIOID-RELATED DISORDERS; PUBLISHING; RESEARCH; STANDARDS;

EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINES AS TOPIC; PUBLICATION BIAS; RESEARCH DESIGN; RESEARCH REPORT; REVIEW LITERATURE AS TOPIC;

EID: 85026751614     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0181927     Document Type: Article

References (68)

1. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002 Oct 9; 288(14):1775–9. PMID: 12365965
2. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002 Oct 16; 288(15):1909–14. PMID: 12377092
3. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003 Feb; 12 (1):18–23. https://doi.org/10.1136/qhc.12.1.18 PMID: 12571340
4. Graham ID, Harrison MB. Evaluation and adaptation of clinical practice guidelines. Evid Based Nurs. 2005 Jul; 8(3):68–72. PMID: 16021701
5. Boyd EA, Akl EA, Baumann M, Curtis JR, Field MJ, Jaeschke R, et al. Guideline Funding and Conflicts of Interest: Article 4 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. Proc Am Thorac Soc. 2012 Dec 15;9(5):234–42.
6. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013; 66(7):726–35. https://doi.org/10.1016/j.jclinepi.2013.02.003 PMID: 23570745
7. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013 Jul; 66(7):719–25. https://doi.org/10.1016/j.jclinepi.2012.03.013 PMID: 23312392
8. Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000 Jan 8; 355(9198):103–6. https://doi.org/10.1016/S0140-6736(99)02171-6 PMID: 10675167
9. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. MMWR Recomm Rep. 2016 Mar 18; 65(1):1–49. https://doi.org/10.15585/mmwr. rr6501e1 PMID: 26987082
10. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011 Apr; 12(4):657–67. https://doi.org/10.1111/j.1526-4637.2011.01075.x PMID: 21392250
11. Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. Increases in Drug and Opioid Overdose Deaths —United States, 2000–2014. Am J Transplant. 2016 Apr 1; 16(4):1323–7.
12. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008 Mar; 11(2 Suppl):S63–88. PMID: 18443641
13. Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014 Dec; 17(6):372–87. https://doi.org/10.1089/pop.2013.0098 PMID: 25075734
14. Green TC, Zaller N, Rich J, Bowman S, Friedmann P. Revisiting Paulozzi et al.’s “Prescription Drug Monitoring Programs and Death Rates from Drug Overdose”: Table 1. Pain Med. 2011 Jun 1; 12(6): 982–5. https://doi.org/10.1111/j.1526-4637.2011.01136.x PMID: 21627763
15. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011 May; 12(5):747–54. https://doi.org/10.1111/j.1526-4637.2011.01062.x PMID: 21332934
16. Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012 Mar; 13(3):434–42. https://doi.org/10.1111/j.1526-4637.2012.01327.x PMID: 22299725
17. Knopf A. White House proposes $1 billion in new funding to treat opioid use disorders. Alcoholism & Drug Abuse Weekly. 2016 Feb 8; 28(6):1–2.
18. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009 Feb; 99(2):221–7. https://doi.org/10.2105/AJPH.2007.131714 PMID: 18799767
19. Bero L. Industry Sponsorship and Research Outcome: A Cochrane Review. JAMA Intern Med. 2013 Apr 8; 173(7):580–1. https://doi.org/10.1001/jamainternmed.2013.4190 PMID: 23440226
20. Campsall P, Colizza K, Straus S, Stelfox HT. Financial Relationships between Organizations That Produce Clinical Practice Guidelines and the Biomedical Industry: A Cross-Sectional Study. PLoS Med. 2016 May; 13(5):e1002029. https://doi.org/10.1371/journal.pmed.1002029 PMID: 27244653
21. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002 Feb 6; 287(5):612–7. PMID: 11829700
22. Cosgrove L, Bursztajn HJ, Krimsky S, Anaya M, Walker J. Conflicts of Interest and Disclosure in the American Psychiatric Association’s Clinical Practice Guidelines. Psychother Psychosom. 2009 Apr 28; 78(4):228–32. https://doi.org/10.1159/000214444 PMID: 19401623
23. Licurse A, Barber E, Joffe S, Gross C. The impact of disclosing financial ties in research and clinical care: a systematic review. Arch Intern Med. 2010 Apr 26; 170(8):675–82. https://doi.org/10.1001/archinternmed.2010.39 PMID: 20421551
24. Li T, Vedula SS, Hadar N, Parkin C, Lau J, Dickersin K. Innovations in Data Collection, Management, and Archiving for Systematic Reviews. Ann Intern Med. 2015 Feb 17; 162(4):287. https://doi.org/10.7326/M14-1603 PMID: 25686168
25. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2008. 672 p.
26. Levi-Minzi MA, Surratt HL, O’Grady CL, Kurtz SP. Finding what works: Predicting health or social service linkage in drug using, African American, female sex workers in Miami, FL. Health Care Women Int. 2016 Jul; 37(7):744–59. https://doi.org/10.1080/07399332.2016.1158262 PMID: 26933839
27. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21; 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072
28. Lang TA, Altman DG. Basic statistical reporting for articles published in biomedical journals: the “Statistical Analyses and Methods in the Published Literature” or the SAMPL Guidelines”. Handbook, European Association of Science Editors. 2013;23–6.
29. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb 6;(2):CD002207. https://doi.org/10.1002/14651858.CD002207.pub4 PMID: 24500948
30. Strings Attached: CADTH’s Database Search Filters | CADTH.ca [Internet]. [cited 2017 Jan 26]. https://www.cadth.ca/resources/finding-evidence/strings-attached-cadths-database-search-filters
31. Institute of Medicine, Board on Health Care Services, Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. National Academies Press; 2011. 290 p.
32. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007 Feb 15; 7:10. https://doi.org/10.1186/1471-2288-7-10 PMID: 17302989
33. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009 Oct; 62(10):1013–20. https://doi.org/10.1016/j.jclinepi.2008.10.009 PMID: 19230606
34. Pieper D, Buechter RB, Li L, Prediger B, Eikermann M. Systematic review found AMSTAR, but not R (evised)-AMSTAR, to have good measurement properties. J Clin Epidemiol. 2015/5; 68(5):574–83. https://doi.org/10.1016/j.jclinepi.2014.12.009 PMID: 25638457
35. Burda BU, Holmer HK, Norris SL. Limitations of A Measurement Tool to Assess Systematic Reviews (AMSTAR) and suggestions for improvement. Syst Rev. 2016 Apr 12; 5:58. https://doi.org/10.1186/ s13643-016-0237-1 PMID: 27072548
36. Popovich I, Windsor B, Jordan V, Showell M, Shea B, Farquhar CM. Methodological quality of systematic reviews in subfertility: a comparison of two different approaches. PLoS One. 2012 Dec 28; 7(12): e50403. https://doi.org/10.1371/journal.pone.0050403 PMID: 23300526
37. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011 Jul 22; 343:d4002. https://doi.org/10.1136/bmj.d4002 PMID: 21784880
38. Sharif MO, Janjua-Sharif FN, Sharif FNJ, Ali H, Ahmed F. Systematic reviews explained: AMSTAR-how to tell the good from the bad and the ugly. Oral Health Dent Manag. 2013 Mar; 12(1):9–16. PMID: 23474576
39. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 Jul 21; 339:b2700. https://doi.org/10.1136/bmj.b2700 PMID: 19622552
40. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1; 4:1. https://doi.org/10.1186/2046-4053-4-1 PMID: 25554246
41. Bryce S, Sloan E, Lee S, Ponsford J, Rossell S. Cognitive remediation in schizophrenia: A methodological appraisal of systematic reviews and meta-analyses. J Psychiatr Res. 2016 Apr; 75:91–106. https://doi.org/10.1016/j.jpsychires.2016.01.004 PMID: 26828372
42. Magellan Healthcare Clinical Practice Guideline Task Force (2015). Introduction to Magellan’s Adopted Clinical Practice Guidelines For the Assessment and Treatment of Patients With Substance Use Disorders.
43. Ministry of Health (2014). New Zealand Practice Guidelines for Opioid Substitution Treatment.
44. National Institute for Health and Care Excellence. (2007). Methadone and buprenorphine for the management of opioid dependence.
45. The Management of Substance Use Disorders Work Group. (2015). Va/DoD Clinical Practice Guidelines For The Management of Substance Use disorders.
46. The College of Physicians & Surgeons of Ontario. (2011). Methadone Maintenance Treatment Program Standards and Clinical Guidelines.
47. Handford, C. (2011). Buprenorphine/Naloxone for Opioid dependence: Clinical practice guideline. Retrieved from https://www.cpso.on.ca/uploadedFiles/policies/guidelines/office/buprenorphine_naloxone_gdlns2011.pdf
48. California Society of Addiction Medicine (2008). Guideline for Physicians Working in California Opioid Treatment Programs. San Francisco.
49. Lingford-Hughes A., Welch S., Peters L., & Nutt D. (2012). BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP. Journal of Psychopharmacology, 26(7), 899–952. https://doi.org/10.1177/0269881112444324 PMID: 22628390
50. Waller, R. (2014). Medication Assisted Treatment Guideline for Opioid Use Disorder.
51. Ford, C., Halliday, K., Lawson, E., Browne, E., Modern, N., Lowe, C., . . . Watson, R. (2011). Royal College of general practitioners guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care substance misuse management in general practice (SMMGP) the alliance written by: Guidance for the use of substitute. Retrieved from http://www.smmgp.org.uk/download/guidance/guidance004.pdf
52. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD004147. https://doi.org/10.1002/14651858.CD004147.pub4 PMID: 21975742
53. Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD002025. https://doi.org/10.1002/14651858.CD002025.pub4 PMID: 19588330
54. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD002209. https://doi.org/10.1002/14651858.CD002209.pub2 PMID: 19588333
55. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD001333. https://doi.org/10.1002/14651858.CD001333.pub3 PMID: 21328250
56. American Society of Addiction Medicine (2015). The National Practice Guideline For the Use of Medications in the Treatment of Addiction involving Opioid Use.
57. Riaz H, Raza S, Khan MS, Riaz IB, Krasuski RA. Impact of Funding Source on Clinical Trial Results Including Cardiovascular Outcome Trials. Am J Cardiol. 2015 Dec 15; 116(12):1944–7. https://doi.org/10.1016/j.amjcard.2015.09.034 PMID: 26611124
58. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31; 326(7400):1167–70. https://doi.org/10.1136/bmj.326.7400.1167 PMID: 12775614
59. Atakpo P, Vassar M. Publication bias in dermatology systematic reviews and meta-analyses. J Derma-tol Sci. 2016 May; 82(2):69–74. https://doi.org/10.1016/j.jdermsci.2016.02.005 PMID: 26925817
60. Detweiler BN, Kollmorgen LE, Umberham BA, Hedin RJ, Vassar BM. Risk of bias and methodological appraisal practices in systematic reviews published in anaesthetic journals: a meta-epidemiological study. Anaesthesia. 2016 Aug; 71(8):955–68. https://doi.org/10.1111/anae.13520 PMID: 27396249
61. Onishi A, Furukawa TA. Publication bias is underreported in systematic reviews published in high-impact-factor journals: metaepidemiologic study. J Clin Epidemiol. 2014 Dec; 67(12):1320–6. https://doi.org/10.1016/j.jclinepi.2014.07.002 PMID: 25194857
62. Roest AM, de Jonge P, Williams CD, de Vries YA, Schoevers RA, Turner EH. Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses. JAMA Psychiatry. 2015 May; 72(5):500–10. https://doi.org/10.1001/jamapsychiatry.2015.15 PMID: 25806940
63. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JPA. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med. 2013 Apr 22; 173(8):664–71. https://doi.org/10.1001/jamainternmed.2013.3018 PMID: 23529078
64. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2; 349:g7647. https://doi.org/10.1136/bmj.g7647 PMID: 25555855
65. PROSPERO [Internet]. [cited 2017 Jan 26]. https://www.crd.york.ac.uk/PROSPERO/
66. Mulrow CD. Rationale for systematic reviews. BMJ. 1994 Sep 3; 309(6954):597–9. PMID: 8086953
67. Van der Wees P, Qaseem A, Kaila M, Ollenschlaeger G, Rosenfeld R, Board of Trustees of the Guidelines International Network (G-I-N). Prospective systematic review registration: perspective from the Guidelines International Network (G-I-N). Syst Rev. 2012 Feb 9; 1:3. https://doi.org/10.1186/2046-4053-1-3 PMID: 22587933
68. Whitehouse S. Text-S. 524-114th Congress (2015–2016): Comprehensive Addiction and Recovery Act of 2016. In: https://www.congress.gov [Internet]. 2016. http://maestro.abanet.org/trk/click?ref=z11aidwdq5_0-2ec8ex33eaf5x07551976&